Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia?

Takekita Y, Serretti A.

Evid Based Ment Health. 2016 Nov;19(4):e25. doi: 10.1136/eb-2015-102215. Epub 2016 Sep 1. No abstract available.

PMID:
27586196
2.

Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.

Citrome L.

Expert Rev Clin Pharmacol. 2016;9(2):169-86. doi: 10.1586/17512433.2016.1121809. Epub 2015 Dec 19. Review.

PMID:
26573020
3.

Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.

Potkin SG, Preda A.

Expert Opin Pharmacother. 2016;17(3):395-407. doi: 10.1517/14656566.2015.1114100. Review.

PMID:
26864352
4.

A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.

Meltzer HY, Risinger R, Nasrallah HA, Du Y, Zummo J, Corey L, Bose A, Stankovic S, Silverman BL, Ehrich EW.

J Clin Psychiatry. 2015 Aug;76(8):1085-90. doi: 10.4088/JCP.14m09741.

5.

Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation.

Potkin SG, Risinger R, Du Y, Zummo J, Bose A, Silverman B, Stankovic S, Ehrich E.

Schizophr Res. 2017 Dec;190:115-120. doi: 10.1016/j.schres.2017.03.003. Epub 2017 Mar 23.

PMID:
28342578
6.

Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.

Shirley M, Perry CM.

Drugs. 2014 Jul;74(10):1097-110. doi: 10.1007/s40265-014-0231-7. Review.

PMID:
24969315
7.

Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.

Cameron C, Zummo J, Desai DN, Drake C, Hutton B, Kotb A, Weiden PJ.

Value Health. 2017 Jul - Aug;20(7):876-885. doi: 10.1016/j.jval.2017.03.010. Epub 2017 May 9. Review.

8.

Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.

Aggarwal A, Gopalakrishna G, Lauriello J.

Clin Schizophr Relat Psychoses. 2016 spring;10(1):58-63. doi: 10.3371/csrp.AGGA.040316. Review.

PMID:
27074333
9.

Long-acting injectable antipsychotics: an underutilized treatment option.

Heres S.

J Clin Psychiatry. 2014 Nov;75(11):1263-5. doi: 10.4088/JCP.14com09541.

10.

Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly.

Biagi E, Capuzzi E, Colmegna F, Mascarini A, Brambilla G, Ornaghi A, Santambrogio J, Clerici M.

Adv Ther. 2017 May;34(5):1036-1048. doi: 10.1007/s12325-017-0507-x. Epub 2017 Apr 5. Review.

11.

Aripiprazole Lauroxil: A Review in Schizophrenia.

Frampton JE.

Drugs. 2017 Dec;77(18):2049-2056. doi: 10.1007/s40265-017-0848-4. Review.

PMID:
29177572
12.

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Edwards NC, Locklear JC, Rupnow MF, Diamond RJ.

Pharmacoeconomics. 2005;23 Suppl 1:75-89.

PMID:
16416763
13.

New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia.

Citrome L.

Expert Rev Neurother. 2013 Jul;13(7):767-83. doi: 10.1586/14737175.2013.811984. Review.

PMID:
23898849
14.

The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials.

Kane JM, Assunção-Talbott S, Eudicone JM, Pikalov A, Whitehead R, Crandall DT.

Schizophr Res. 2008 Oct;105(1-3):208-15. doi: 10.1016/j.schres.2008.06.018. Epub 2008 Sep 14. Erratum in: Schizophr Res. 2009 Feb;107(2-3):334-5.

PMID:
18790605
15.

Initiation of aripiprazole once-monthly in patients with schizophrenia.

Raoufinia A, Baker RA, Eramo A, Nylander AG, Landsberg W, Kostic D, Larsen F.

Curr Med Res Opin. 2015 Mar;31(3):583-92. doi: 10.1185/03007995.2015.1006356. Epub 2015 Feb 5. Review.

PMID:
25586294
16.

Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).

de Arce Cordón R, Eding E, Marques-Teixeira J, Milanova V, Rancans E, Schreiner A.

Eur Arch Psychiatry Clin Neurosci. 2012 Mar;262(2):139-49. doi: 10.1007/s00406-011-0220-8. Epub 2011 Aug 2.

PMID:
21809168
17.

[Efficacy of aripiprazole (amdoal) in the long-term treatment of schizophrenia].

Tsukarzi EE.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(3):94-7. Review. Russian. No abstract available.

PMID:
23755402
18.

Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics.

Peters-Strickland T, Zhao C, Perry PP, Eramo A, Salzman PM, McQuade RD, Johnson BR, Sanchez R.

CNS Spectr. 2016 Dec;21(6):460-465. Epub 2016 Aug 17.

PMID:
27531181
19.

Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists.

Fagiolini A, Alfonsi E, Amodeo G, Cenci M, Di Lella M, Farinella F, Ferraiuolo F, Fraguas D, Loparco N, Gutierrez-Rojas L, Mignone ML, Pataracchia G, Pillai G, Russo F, Sanchez-Gistau V, Spinogatti F, Toscano M, Villari V, De Filippis S.

Expert Opin Drug Saf. 2016;15(4):449-55. doi: 10.1517/14740338.2016.1155553. Epub 2016 Mar 9.

PMID:
26886162
20.

The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia.

Cutler AJ, Marcus RN, Hardy SA, O'Donnell A, Carson WH, McQuade RD.

CNS Spectr. 2006 Sep;11(9):691-702; quiz 719.

PMID:
16946694

Supplemental Content

Support Center